Corcept Therapeutics Inc (CORT) - News Archive

Corcept Therapeutics: Navigating Financial Fortitude and Pioneering Oncologic Innovations In a landscape marked by relentless dynamism and evolving healthcare paradigms, Corcept Therapeutics Incorporated (NASDAQ: CORT),...

Promising Advances in Ovarian Cancer Treatment Corcept Therapeutics, a company known for its work in endocrinologic and oncologic treatments, recently unveiled promising data from its Phase 3 ROSELLA trial at the 2025 E...

Corcept Therapeutics Advances Oncology Portfolio with Marketing Authorization Application for Relacorilant in Platinum-Resistant Ovarian Cancer In a significant stride for oncological therapeutics, Corcept Therapeutics...

: Recent developments from Corcept Therapeutics highlight promising advancements in the treatment of both platinum-resistant ovarian cancer and amyotrophic lateral sclerosis (ALS). Comprehensive analyses from the Phase...

FDA Accepts Corcept s New Drug Application for Relacorilant to Address Platinum-Resistant Ovarian Cancer In a significant development for the field of oncology and therapeutic treatments, Corcept Therapeutics Incorporat...

Advancing Therapeutics in ALS: Corcept s Promising Phase 2 Results for Dazucorilant In an exciting development for the treatment of Amyotrophic Lateral Sclerosis (ALS), Corcept Therapeutics Incorporated recently unveile...

In the latest corporate update, Corcept Therapeutics Incorporated (NASDAQ: CORT), a pioneering force in the pharmaceutical sector, showcased strong first-quarter results for the fiscal year ending March 31, 2025. As the...

In an important development for cancer treatment, Corcept Therapeutics Incorporated is set to present data from its pivotal Phase 3 ROSELLA trial of relacorilant in combination with nab-paclitaxel for patients suffering...

The management of Type 2 diabetes (T2D), particularly in patients with difficult-to-control conditions, poses significant challenges to healthcare providers. Recently, Corcept Therapeutics Incorporated announced the pub...

: In a significant advancement in the treatment of platinum-resistant ovarian cancer, Corcept Therapeutics Inc. has reported that the primary endpoint of its phase-3 ROSELLA study evaluating Relacorilant has been achiev...

In the world of biotech, innovation often walks a tightrope, balancing the exhilarating promise of breakthroughs with the sobering validation of regulatory hurdles. As Corcept Therapeutics Incorporated takes bold steps...

Corcept Therapeutics Submits New Drug Application Amidst Rising Revenues and Competitive Challenges Corcept Therapeutics Inc. recently announced the submission of a New Drug Application (NDA) for its innovative treatmen...

Corcept Therapeutics Incorporated has made significant strides in the development of cortisol modulators with the recent submission of a New Drug Application (NDA) for relacorilant, aimed at treating endogenous hypercor...

In a significant development for the management of hypercortisolism, commonly known as Cushing s syndrome, Corcept Therapeutics Incorporated recently announced the successful achievement of the primary endpoint in the t...

Corcept Therapeutics Advances in ALS Research with Promising Phase 2 Study Results and Robust Financial Performance In a noteworthy development for the medical community and patients affected by neurodegenerative diseas...

In a significant stride towards addressing the unmet medical needs of patients suffering from Amyotrophic Lateral Sclerosis (ALS), Corcept Therapeutics Incorporated has unveiled promising results from its Phase 2 DAZALS...

Corcept Announces Results from Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association s Scientific SessionsCorcept Therapeutics Incorporated recently revealed the findings from the prevalence phase...

Relacorilant Shows Positive Results in Phase 3 GRACE Trial for Hypercortisolism MENLO PARK, Calif., June 03, 2024 - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage biopharmaceutical company speciali...

In a significant step forward for Corcept Therapeutics Incorporated, the Phase 3 clinical trial of their experimental drug, relacorilant, has successfully achieved its primary endpoint. The medication has shown promisin...

Corcept, widely acclaimed for its novel approach in curbing diverse disorders by modulating the effects of the hormone cortisol, has completed enrollment for the fourth phase of its CATALYST trial. The trial aims to est...